Evolus Skyrockets, making a double bullish move, on the preliminary report
Shares of Evolution (EOLs) made a double bull move on Tuesday — retaking their 50-day and 200-day moving averages — on strong first-quarter report and guidance for 2025.
How to buy stocks: IBD’s four pillars of investing
Leerink Partners analyst Mark Goodman said in a report that the medical beauty company had already announced fourth-quarter sales of $79 million.
This helped the Evols raise its sights on 2024. In November, the company lowered its guidance for the year by 1%, causing the stock to dive 15% for one day. In six days, the Evols’ stock is down 29 percent.
“After the stock reaction to that November announcement, which we always thought was confusing and overblown, the company will probably make everyone feel better with today’s PR[press release],” Goodman said. “We liked the stock at $17 in November, so today they like it at $13-$14 with this kind of announcement.”
Evolus stock rose 28.3 percent to 13.48. Shares rose above their 50-day and 200-day lines — a bullish sign — and touched their highest point since early November.
The Evolus 2025 Guide
In addition to the strong first-quarter report, Evolus guided for 2025 sales of $345 million to $355 million, setting the Street View at $352 million, Mizuho Securities analyst Yu Er said in a note to clients.
The company now expects the Food and Drug Administration to approve Evolysse Formula and Evolysse Smooth injectable hyaluronic acid gels in the second quarter. These gels help reduce fine lines and wrinkles.
Injectable hyaluronic acid gels Evolyse and Estime are expected to generate 8 to 10 percent of 2025 sales.
The pending approval will transform Evolus from a single-product company to a “multi-product innovation,” CEO David Moatazedi said in a written statement. Evols main product is Jeuveau as a neurotoxin filler. ABV()ABBV) Botox
Botox is simply the market leader – the name is synonymous with wrinkles. According to FactSet, as a cosmetic drug, Botox is estimated to bring in $761 million in sales in the fourth quarter. But Jeuveau is growing rapidly, growing from 22% to 42% of sales over the past four quarters. Sales of Botox cosmetics have grown 12% over the past four quarters, including a quarter when sales fell 4%.
Follow Alison Gatlin on X/Twitter @IBD_AGAtlin.
You may also like:
Why the top 4% reserve health to 13 months high and high profit zone
Walgreens will copy 40% of Sprint’s opioid prescriptions, according to DOJ
Looking for the next big stock market winners? Start with these 3 steps
Stocks to Buy and Watch: Top IPOs, Large and Small Caps, Growth Stocks
Want to make quick profits and avoid big losses? Try SwingTrader